应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ABBV 艾伯维公司
耶稣受难日休市 03-28 16:00:00 EDT
182.10
+1.75
+0.97%
盘后
182.10
+0.00
0.00%
19:58 EDT
最高
182.30
最低
180.30
成交量
541.87万
今开
181.00
昨收
180.35
日振幅
1.11%
总市值
3,224亿
流通市值
3,217亿
总股本
17.71亿
成交额
9.85亿
换手率
0.31%
流通股本
17.67亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
BUZZ-受艾伯维收购交易影响,兰多斯生物制药公司业绩大涨
Reuters · 03-25
BUZZ-受艾伯维收购交易影响,兰多斯生物制药公司业绩大涨
更新版 1-艾伯维通过兰多斯交易加强免疫疾病药物管线
Reuters · 03-25
更新版 1-艾伯维通过兰多斯交易加强免疫疾病药物管线
艾伯维将收购兰多斯,扩大免疫相关疾病的产品线
Reuters · 03-25
艾伯维将收购兰多斯,扩大免疫相关疾病的产品线
华东医药:ELAHERE®(索米妥昔单抗注射液)获美国FDA完全批准
财经网 · 03-25
华东医药:ELAHERE®(索米妥昔单抗注射液)获美国FDA完全批准
艾伯维(ABBV.US)“first-in-class”ADC获FDA完全批准
智通财经 · 03-23
艾伯维(ABBV.US)“first-in-class”ADC获FDA完全批准
美国 FDA 全面批准艾伯维的卵巢癌疗法
Reuters · 03-23
美国 FDA 全面批准艾伯维的卵巢癌疗法
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
Reuters · 03-14
BUZZ-穆迪称因GLP-1药物推动制药业前景转为 "积极
艾伯维肺癌数据照亮ADC加速审批之路,但未达到早期基准
亿欧网 · 02-29
艾伯维肺癌数据照亮ADC加速审批之路,但未达到早期基准
为穿越周期 艾伯维(ABBV.US)做了哪些改变?
智通财经网 · 02-25
为穿越周期 艾伯维(ABBV.US)做了哪些改变?
制药巨头艾伯维拟出售130亿美元债券,为并购作准备
金十数据 · 02-22
制药巨头艾伯维拟出售130亿美元债券,为并购作准备
传艾伯维(ABBV.US)拟出售至少130亿美元债券为并购融资
智通财经 · 02-22
传艾伯维(ABBV.US)拟出售至少130亿美元债券为并购融资
据彭博社报道,艾伯维希望出售至少 130 亿美元债券为并购提供资金
Reuters · 02-22
据彭博社报道,艾伯维希望出售至少 130 亿美元债券为并购提供资金
重磅:艾伯维换帅!修美乐告别“药王”,伊布替尼遭竞品围剿,如何破局?
医药经济报 · 02-21
重磅:艾伯维换帅!修美乐告别“药王”,伊布替尼遭竞品围剿,如何破局?
艾伯维称理查德-冈萨雷斯将辞去首席执行官一职
Reuters · 02-20
艾伯维称理查德-冈萨雷斯将辞去首席执行官一职
美国研究综述-空气化工产品公司、Hubspot、麦当劳
Reuters · 02-06
美国研究综述-空气化工产品公司、Hubspot、麦当劳
BUZZ-券商观点:艾伯维的免疫学药物将减轻近期损失
Reuters · 02-05
BUZZ-券商观点:艾伯维的免疫学药物将减轻近期损失
艾伯维2023年财报:修美乐144亿美元,自免新产品增长强劲
医药魔方 · 02-03
艾伯维2023年财报:修美乐144亿美元,自免新产品增长强劲
BUZZ--美国股票走势-艾伯维、雪佛龙、美泰
Reuters · 02-03
BUZZ--美国股票走势-艾伯维、雪佛龙、美泰
加载更多
公司概况
公司名称:
艾伯维公司
所属市场:
NYSE
上市日期:
--
主营业务:
艾伯维公司注册成立于2012年4月10日,是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法,来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域,包括类风湿性关节炎,牛皮癣和克罗恩病,银屑病和克罗恩病;低睾酮,HIV,子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。
发行价格:
--
{"stockData":{"symbol":"ABBV","market":"US","secType":"STK","nameCN":"艾伯维公司","latestPrice":182.1,"timestamp":1711656000000,"preClose":180.35,"halted":0,"volume":5418687,"hourTrading":{"tag":"盘后","latestPrice":182.1,"preClose":182.1,"latestTime":"19:58 EDT","volume":476145,"amount":86705522.4964,"timestamp":1711670331834},"delay":0,"floatShares":1766776525,"shares":1770646983,"eps":2.72,"marketStatus":"耶稣受难日休市","marketStatusCode":7,"change":1.75,"latestTime":"03-28 16:00:00 EDT","open":181,"high":182.3,"low":180.3,"amount":984664836.2355,"amplitude":0.01109,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.72,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1711958400000},"adr":0,"adjPreClose":180.35,"adrRate":0,"dividendRate":0.032894,"preHourTrading":{"tag":"盘前","latestPrice":180.99,"preClose":180.35,"latestTime":"09:29 EDT","volume":47142,"amount":8502864.885359999,"timestamp":1711632594017},"postHourTrading":{"tag":"盘后","latestPrice":182.1,"preClose":182.1,"latestTime":"19:58 EDT","volume":476145,"amount":86705522.4964,"timestamp":1711670331834},"volumeRatio":1.145099},"requestUrl":"/m/hq/s/ABBV","defaultTab":"news","newsList":[{"id":"2422179635","title":"BUZZ-受艾伯维收购交易影响,兰多斯生物制药公司业绩大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2422179635","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422179635?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:24","pubTimestamp":1711373062,"startTime":"0","endTime":"0","summary":" 3月25日 - ** 疗法开发商兰多斯生物制药公司 的股价盘前上涨两倍多,达到23.56美元 ** 艾伯维 将以最高2.12亿美元的价格收购该公司 ** 根据交易,ABBV将以每股20.42美元的现金收购Landos,总价约为1.375亿美元,比LABP上周五收盘价溢价160.8%。** ABBV还将向Landos股东支付每股最多11.14美元的额外里程碑付款,总额约为7500万美元。** 截至上一交易日收盘,LABP 的股价比去年同期翻了一番多","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422514079","title":"更新版 1-艾伯维通过兰多斯交易加强免疫疾病药物管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2422514079","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422514079?lang=zh_cn&edition=full","pubTime":"2024-03-25 21:03","pubTimestamp":1711371806,"startTime":"0","endTime":"0","summary":"艾伯维的大片药物 Rinvoq 已被批准用于治疗这种疾病,同时该公司还在寻求美国食品药品管理局批准其另一种主要药物 Skyrizi。根据这项交易,艾伯维将以每股 20.42 美元的现金收购兰多斯,总价约为 1.375 亿美元。在短暂停牌后,兰多斯的股价在收盘前飙升至 22.13 美元。两家公司表示,交易预计将在第二季度完成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422519043","title":"艾伯维将收购兰多斯,扩大免疫相关疾病的产品线","url":"https://stock-news.laohu8.com/highlight/detail?id=2422519043","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422519043?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:37","pubTimestamp":1711370251,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社3月25日 - 艾伯维 周一表示,将以不超过2.12亿美元的价格收购药物开发商兰多斯生物制药 ,这家Humira生产商的目标是扩大其治疗免疫系统相关疾病的药物产品线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422249595","title":"华东医药:ELAHERE®(索米妥昔单抗注射液)获美国FDA完全批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2422249595","media":"财经网","top":-1,"share":"https://www.laohu8.com/m/news/2422249595?lang=zh_cn&edition=full","pubTime":"2024-03-25 17:23","pubTimestamp":1711358621,"startTime":"0","endTime":"0","summary":"3月25日,华东医药公告称,公司全资子公司杭州中美华东制药有限公司(简称“中美华东”)美国合作方AbbVieInc.(简称“AbbVie”)对外宣布,其用于治疗铂耐药卵巢癌的ADC药物ELAHERE®(索米妥昔单抗注射液)获得美国食品药品监督管理局(FDA)完全批准。公告显示,ELAHERE®为中美华东与ImmunoGen,Inc.(目前已被AbbVie收购)合作开发的针对叶酸受体α靶点的ADC药物,由FRα结合抗体、可裂解的连接子和美登木素生物碱DM4组成。中美华东拥有该产品在大中华区(含中国大陆、香港、澳门和台湾地区)的独家临床开发及商业化权益。(深交所)(编辑:周彤)关键字:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325172405791c9a17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240325172405791c9a17&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2421701698","title":"艾伯维(ABBV.US)“first-in-class”ADC获FDA完全批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2421701698","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2421701698?lang=zh_cn&edition=full","pubTime":"2024-03-23 08:15","pubTimestamp":1711152900,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月23日,艾伯维宣布,美国FDA已完全批准其“first-in-class”抗体偶联药物Elahere用于治疗叶酸受体α(FRα)阳性、铂类耐药的上皮性卵巢癌、输卵管癌或原发性腹膜癌患者,这些患者既往接受过至多3种全身治疗方案。Elahere是一款将与FRα结合的人源化单克隆抗体,与能够产生细胞毒性的DM4分子通过二硫键连接起来的“first-in-class”抗体偶联药物。2023年11月,艾伯维与ImmunoGen达成协议,以101亿美元收购该公司并获得Elahere。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1091057.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421825550","title":"美国 FDA 全面批准艾伯维的卵巢癌疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2421825550","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2421825550?lang=zh_cn&edition=full","pubTime":"2024-03-23 02:35","pubTimestamp":1711132528,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社3月22日 - 美国食品和药物管理局(FDA) 美国食品和药物管理局周五表示,它已批准艾伯维公司 的 \"制导导弹 \"癌症疗法Elahere用于治疗一种卵巢癌和相关癌症的成年患者,这些患者此前已接受过一至三种治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2419983375","title":"BUZZ-穆迪称因GLP-1药物推动制药业前景转为 \"积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2419983375","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2419983375?lang=zh_cn&edition=full","pubTime":"2024-03-14 22:35","pubTimestamp":1710426957,"startTime":"0","endTime":"0","summary":" 3月14日 - ** 穆迪评级公司称,GLP-1 和其他大片药物已将美国制药业信贷展望从 \"稳定 \"提升至 \"积极\"。** 评级机构表示,该行业的增长将受益于大片药物使用量的增加,包括诺和诺德 和礼来 的GLP-1糖尿病和减肥治疗药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2415677015","title":"艾伯维肺癌数据照亮ADC加速审批之路,但未达到早期基准","url":"https://stock-news.laohu8.com/highlight/detail?id=2415677015","media":"亿欧网","top":-1,"share":"https://www.laohu8.com/m/news/2415677015?lang=zh_cn&edition=full","pubTime":"2024-02-29 15:05","pubTimestamp":1709190345,"startTime":"0","endTime":"0","summary":"AbbVie旨在加速批准其用于肺癌患者的c-Met抗体-药物偶联物(ADC),telisotuzumab vedotin(Teliso-V)。在光度试验中,Teliso-V在高c-Met表达的患者中显示出35%的缓解率,在中等表达的患者中显示出23%的缓解率。尽管这些比率低于早期数据,但AbbVie报告称总体生存率中位数有所提高,并计划与监管机构讨论加速批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022915171187d090ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022915171187d090ca&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2414039494","title":"为穿越周期 艾伯维(ABBV.US)做了哪些改变?","url":"https://stock-news.laohu8.com/highlight/detail?id=2414039494","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2414039494?lang=zh_cn&edition=full","pubTime":"2024-02-25 09:43","pubTimestamp":1708825424,"startTime":"0","endTime":"0","summary":"一代\"药王\"修美乐的谢幕,使艾伯维业绩受到较大冲击。为了培养新的增长引擎,穿越周期,过去一年,艾伯维做了哪些改变?","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240225/20240225094519_14475.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240225/20240225094519_14475.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1076283.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2413234890","title":"制药巨头艾伯维拟出售130亿美元债券,为并购作准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2413234890","media":"金十数据","top":-1,"share":"https://www.laohu8.com/m/news/2413234890?lang=zh_cn&edition=full","pubTime":"2024-02-22 11:29","pubTimestamp":1708572585,"startTime":"0","endTime":"0","summary":"去年年底,这家制药巨头同意收购ImmunoGen、Cerevel两家公司。","market":"us","thumbnail":"https://static.tigerbbs.com/202d5f7a31e9e8725ee64c650896759f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/202d5f7a31e9e8725ee64c650896759f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=132798&type=news&data_type=0","is_publish_highlight":true,"gpt_icon":1},{"id":"2413385822","title":"传艾伯维(ABBV.US)拟出售至少130亿美元债券为并购融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2413385822","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2413385822?lang=zh_cn&edition=full","pubTime":"2024-02-22 09:51","pubTimestamp":1708566696,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,据知情人士透露,艾伯维正寻求出售至少130亿美元的公司债券,为其收购ImmunoGen和Cerevel Therapeutics提供资金。此次发行的规模可能会有所变化,并将在发行当天确定。艾伯维没有立即回应置评请求。据悉,去年12月,艾伯维接连宣布了两项收购——以87亿美元收购Cerevel的计划,以及最近完成的以101亿美元收购ImmunoGen的交易。此后,艾伯维表示,计划将重点放在规模较小的交易上,以支持其在未来十年的增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022209545281a631c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022209545281a631c9&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2413288928","title":"据彭博社报道,艾伯维希望出售至少 130 亿美元债券为并购提供资金","url":"https://stock-news.laohu8.com/highlight/detail?id=2413288928","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2413288928?lang=zh_cn&edition=full","pubTime":"2024-02-22 07:03","pubTimestamp":1708556582,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社2月21日 - 彭博新闻社周三援引知情人士的话报道,艾伯维 正寻求出售至少130亿美元的公司债券,以帮助其为收购ImmunoGen和Cerevel Therapeutics 提供资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2413441032","title":"重磅:艾伯维换帅!修美乐告别“药王”,伊布替尼遭竞品围剿,如何破局?","url":"https://stock-news.laohu8.com/highlight/detail?id=2413441032","media":"医药经济报","top":-1,"share":"https://www.laohu8.com/m/news/2413441032?lang=zh_cn&edition=full","pubTime":"2024-02-21 20:02","pubTimestamp":1708516928,"startTime":"0","endTime":"0","summary":"在其任职期间,艾伯维的市值从最初的540亿美元上涨至如今的3103亿美元。然而,不仅修美乐专利到期的“达摩克利斯之剑”已经落下,伊布替尼也遭遇了竞品围剿,销量正面临下滑。在国内BTK抑制剂市场中,先声药业的BTK抑制剂伊布替尼胶囊获国家药监局上市批准,成为该产品首仿。艾伯维的支柱性产品修美乐营收144.04亿美元,同比下降32.2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022120055087a8f45d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024022120055087a8f45d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2412817089","title":"艾伯维称理查德-冈萨雷斯将辞去首席执行官一职","url":"https://stock-news.laohu8.com/highlight/detail?id=2412817089","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2412817089?lang=zh_cn&edition=full","pubTime":"2024-02-20 22:05","pubTimestamp":1708437907,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 路透社2月20日 - 艾伯维 周二表示,理查德-冈萨雷斯(Richard Gonzalez)将辞去该公司首席执行官的职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409477656","title":"美国研究综述-空气化工产品公司、Hubspot、麦当劳","url":"https://stock-news.laohu8.com/highlight/detail?id=2409477656","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409477656?lang=zh_cn&edition=full","pubTime":"2024-02-06 20:33","pubTimestamp":1707222822,"startTime":"0","endTime":"0","summary":" 路透2月6日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括空气化工产品公司、Hubspot 和麦当劳。要闻 * 空气化工产品公司 :摩根大通将目标价从295美元下调至270美元 * Hubspot Inc :杰富瑞将目标价从620美元上调至695美元 * 麦当劳 :BTIG将其目标价从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2409487049","title":"BUZZ-券商观点:艾伯维的免疫学药物将减轻近期损失","url":"https://stock-news.laohu8.com/highlight/detail?id=2409487049","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2409487049?lang=zh_cn&edition=full","pubTime":"2024-02-05 22:06","pubTimestamp":1707142017,"startTime":"0","endTime":"0","summary":" 2月5日 - ** 艾伯维 周五将其免疫学药物Skyrizi和Rinvoq 2027年的销售预测 ,达到270亿美元,比之前的预测增加了60亿美元。关注 Skyrizi 和 Rinvoq ** 富国银行 称,由于 Skyrizi 和 Rinvoq 将超越 Humira,ABBV 的 \"增长故事看起来更好了\"。** Raymond James 认为 2024 年应恢复温和的运营增长,2025 年将实现强劲增长 ** Morningstar 称,公司现有的产品组合将减轻艾伯维主要药物 Humira 需求放缓带来的损失。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2408894967","title":"艾伯维2023年财报:修美乐144亿美元,自免新产品增长强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2408894967","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2408894967?lang=zh_cn&edition=full","pubTime":"2024-02-03 08:31","pubTimestamp":1706920299,"startTime":"0","endTime":"0","summary":"2月2日,艾伯维公布了2023年业绩,全年净收入543.18亿美元,较往年有所下滑。点击下载2023年艾伯维财报新闻稿艾伯维主要聚焦于5大疾病领域,包括免疫、肿瘤、神经科学、美容以及眼科。2024年,Skyrizi也有望获FDA批准溃疡性结肠炎新适应症。点击下载2023年艾伯维财报PPT基于两款产品的增长势头,艾伯维也将2027年的销售预期上调60亿美元至270亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402030840588166318d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202402030840588166318d&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2408953326","title":"BUZZ--美国股票走势-艾伯维、雪佛龙、美泰","url":"https://stock-news.laohu8.com/highlight/detail?id=2408953326","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2408953326?lang=zh_cn&edition=full","pubTime":"2024-02-03 03:01","pubTimestamp":1706900480,"startTime":"0","endTime":"0","summary":" * 个股异动的 Eikon 搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 2月2日 - 周五美国股市大涨,基准标普500指数创下新纪录,原因是投资者对Meta Platforms和亚马逊公司强劲的季报感到欢欣鼓舞,而强劲的就业报告则抑制了投资者的乐观情绪。美东时间13:31,道琼斯工业平均指数 上涨0.20%,报38597.82点。标普500指数 上涨0.94%,报4952.22点;纳斯达克综合指数 上涨1.52%,报15595.63点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abbvie.com","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.0174},{"period":"3month","weight":0.1751},{"period":"6month","weight":0.2217},{"period":"1year","weight":0.1525},{"period":"ytd","weight":0.1751}],"compareEarnings":[{"period":"1week","weight":0.0017},{"period":"1month","weight":0.0318},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.2236},{"period":"1year","weight":0.3033},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"艾伯维公司注册成立于2012年4月10日,是一家全球性的、以研究为基础的生物制药公司。Abbvie公司从事开发和销售先进的疗法,来解决一些世界上最复杂和严重的疾病。Abbvie公司的产品主要集中在慢性自身免疫性疾病领域,包括类风湿性关节炎,牛皮癣和克罗恩病,银屑病和克罗恩病;低睾酮,HIV,子宫内膜异位症;甲状腺疾病;帕金森病;和并发症的慢性肾脏疾病和囊性纤维化相关的或其他健康问题。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.023334},{"month":2,"riseRate":0.833333,"avgChangeRate":0.030818},{"month":3,"riseRate":0.75,"avgChangeRate":0.006329},{"month":4,"riseRate":0.727273,"avgChangeRate":0.026869},{"month":5,"riseRate":0.727273,"avgChangeRate":0.007528},{"month":6,"riseRate":0.454545,"avgChangeRate":0.004829},{"month":7,"riseRate":0.454545,"avgChangeRate":0.00558},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.006918},{"month":9,"riseRate":0.454545,"avgChangeRate":0.007981},{"month":10,"riseRate":0.636364,"avgChangeRate":0.011149},{"month":11,"riseRate":0.818182,"avgChangeRate":0.080758},{"month":12,"riseRate":0.727273,"avgChangeRate":0.032678}],"exchange":"NYSE","name":"艾伯维公司","nameEN":"AbbVie"},"APP":{"userAgent":"claudebot","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.3","shortVersion":"4.22.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾伯维公司,ABBV,艾伯维公司股票,艾伯维公司股票老虎,艾伯维公司股票老虎国际,艾伯维公司行情,艾伯维公司股票行情,艾伯维公司股价,艾伯维公司股市,艾伯维公司股票价格,艾伯维公司股票交易,艾伯维公司股票购买,艾伯维公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾伯维公司(ABBV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾伯维公司(ABBV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}